Silver Book

Silver Book Fact

Infection control program reduced hospital-acquired HAIs by > 1/3

A multimodal infection control program reduced the rate of hospital-acquired HAIs by more than 1/3 and improved quality of care and patient outcomes.

Ebnother, Corina, Beate Tanner, Flavia Schmid, Vittoria La Rocca, Ivo Heinzer, and Thomas Bregenzer. Impact of an Infection Control Program on the Prevalence of Nonsocomial Infections at a Tertiary Care Center in Switzerland. Infect Control Hosp Epidemiol. 2008; 29(1): 38-43. http://www.jstor.org/stable/10.1086/524330

Reference

Title
Impact of an Infection Control Program on the Prevalence of Nonsocomial Infections at a Tertiary Care Center in Switzerland
Publication
Infect Control Hosp Epidemiol
Publication Date
2008
Authors
Ebnother, Corina, Beate Tanner, Flavia Schmid, Vittoria La Rocca, Ivo Heinzer, and Thomas Bregenzer
Volume & Issue
Volume 29, Issue 1
Pages
38-43
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Publications

Healthcare-Associated Infections Factsheet

 https://www.silverbook.org/wp-content/uploads/2015/06/Screen-Shot-2015-06-30-at-3.02.28-PM.png Thumbnail

Related Facts

  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
  • Over 8 years infection control practices saved ~27,000 lives and $1.8 billion
    Infection control practices saved an estimated 27,000 lives and $1.8 billion in medical costs between 2001 and 2009.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Infection control program reduced hospital-acquired HAIs by > 1/3
    A multimodal infection control program reduced the rate of hospital-acquired HAIs by more than 1/3 and improved quality of care and patient outcomes.  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.